Chirec

Brussels 23 trials 14 recruiting

23 Registered trials

14 Currently recruiting

Organisation

Chirec

Location

Brussels, Belgium

Identifier

ORG-100023357

Address

Triomflaan 201, 1160, Belgium

Departments

032010: Oncology
Centre de procréation médicalement assistée
Chirec Cancer Institute
Chirec Cancer Institute (CCI)
Gastroenterology
Medical Oncology
NA
Neonatology
Oncology
Orthopeady
Pneumology
Pneumology and thoracic oncology
Respiratory Disease
Respiratory Diseases

Clinical trials at this site (23)

Search interface

DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t… Pending

2025-520565-51-00 small cell lung cancer 5
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after… Pending

2025-521908-22-00 EGFR-mutated Non-small Cell Lung Cancer 10
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending

2025-523586-18-00 Non-Small Cell Lung Cancer 5
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A prospective multicentre single-arm study in adults to evaluate the safety and preliminary efficacy of the autologous 3D osteogenic implant… Recruiting

2024-517762-42-01 recalcitrant lower limb nonunion 7 2018-08-02
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal… Recruiting

2024-512302-25-00 Resected or Unresectable KRAS G12C-mutant Non-Small Cel 5 2025-06-06
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-514281-39-00 Metastatic Squamous Non-small Cell Lung Cancer Whose Tu 5 2025-02-14
A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-515008-38-00 Metastatic Non-squamous Non-small Cell Lung Cancer Whos 5 2025-02-14
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Evaluating the Diagnostic Performance of Human Epidermal Growth Factor Receptor 2 (HER2) targeted Positron Emission Tomography and Computed … Recruiting

2024-511419-22-00 Hormone receptor positive/HER2 negative, triple-negativ 10 2024-09-03
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal canc… Recruiting

2023-506703-26-00 locally advanced rectal cancer 5 2024-02-07
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting

2022-502046-28-00 HER2-Positive, PIK3CA Mutated, Locally Advanced or Meta 5 2023-12-22
Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline … Recruiting

2022-501181-22-01 Pancreatic adenocarcinoma 4 2023-02-06
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Doxapram versus placebo in preterm newborns: An international double blinded multicenter randomized controlled trial Recruiting

2024-515625-29-00 Apnea of prematurity 5 2020-06-16
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive… Ended

2023-505249-24-00 HER2-positive metastatic breast cancer 5 2021-05-27
A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III r… Ended

2024-516554-22-00 Locally-advanced stage II-III rectal cancer 4 2021-03-29
A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Ended

2022-502798-40-00 Patients with resected colon carcinoma 5 2017-07-31
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
A prospective interventional randomized controlled trial to assess the effect of low dose acetylsalicylic acid as a preventive treatment of … Ended

2024-516816-72-00 preeclampsia 5 2022-04-27